eAbstracts: The Therapeutic Mode of Action of 4-aminopyridine in Cerebellar Ataxia


This study aimed to show that therapeutic concentrations of 4-AP do not increase the inhibitory drive of cerebellar Purkinje cells.

Journal:The Journal of Neuroscience (May 26, 2010)

Authors: Alviña K, Khodakhah K

Purpose: To “show that, in contrast to what is commonly believed, therapeuticconcentrations of 4-AP do not increase the inhibitory driveof cerebellar Purkinje cells.”

Results: “4-AP restores the severelydiminished precision of pacemaking in Purkinje cells of EA2mutant mice by prolonging the action potential and increasingthe action potential afterhyperpolarization. Consistent withthis mode of action, the therapeutic efficacy of 4-AP was comparable,and not additive, to chlorzoxazone, an activator of Ca2+-dependentK+ channels that also restores the precision of Purkinje cellpacemaking. The likely target of 4-AP at the concentrationsused are the Kv1 family of K+ channels, possibly the Kv1.5 subtype.Because at higher concentrations 4-AP blocks a large array ofK+ channels and is a proconvulsant, use of selective Kv1 channelblockers is likely to be a safer substitute for treatment ofcerebellar ataxia.”

Click here to access this third-party resource.

More from the recent literature on Ataxia:

  • Assessment of Brain White Matter Fiber Bundle Atrophy in Patients with Friedreich Ataxia
  • Activation of Ataxia Telangiectasia Muted Under Experimental Models and Human Parkinson's Disease
Related Videos
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Stephanie Nahas, MD, MSEd | Credit: Jefferson Health
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy
John Harsh, PhD
© 2024 MJH Life Sciences

All rights reserved.